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A B S T R A C T
Background
Subfertility affects 15% of couples and represents the inability to conceive naturally following 12 months of regular unprotected
sexual intercourse. Assisted reproduction refers to procedures involving the in vitro handling of both human gametes and represents
a key option for many subfertile couples. Most women undergoing assisted reproduction treatment will reach the stage of embryo
transfer (ET) but the proportion of embryos that successfully implant following ET has remained small since the mid-1990s. Human
chorionic gonadotropin (hCG) is a hormone synthesised and released by the syncytiotrophoblast and has a fundamental role in embryo
implantation and the early stages of pregnancy. Intrauterine administration of synthetic or natural hCG via an ET catheter during
a mock procedure around the time of ET is a novel approach that has recently been suggested to improve the outcomes of assisted
reproduction.
Objectives
To investigate whether the intrauterine administration of hCG around the time of ET improves the clinical outcomes in subfertile
women undergoing assisted reproduction.
Search methods
We performed a comprehensive literature search of the Cochrane Gynaecology and Fertility Group Specialised Register, Cochrane
Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, PsycINFO, registers of ongoing trials and
reference lists of all included studies and relevant reviews (from inception to 10 November 2015), in consultation with the Cochrane
Gynaecology and Fertility Group Trials Search Co-ordinator.
Selection criteria
We included all randomised controlled trials (RCTs) evaluating intrauterine administration of hCG around the time of ET in this
review irrespective of language and country of origin.
1Intrauterine administration of human chorionic gonadotropin (hCG) for subfertile women undergoing assisted reproduction (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Data collection and analysis
Two authors independently selected studies, assessed risk of bias, extracted data from studies and attempted to contact the authors
where data were missing. We performed statistical analysis using Review Manager 5 in accordance with the Cochrane Handbook for
Systematic Reviews of Interventions. We assessed evidence quality using GRADE methods.
Main results
Twelve RCTs investigated the effect of intrauterine administration of hCG for 4038 subfertile women undergoing assisted reproduction.
The intra-cavity hCG (IC-hCG) was administered in variable doses at different timings before the ET. The source of hCG was from
the urine of pregnant women or from cell cultures using recombinant DNA technology.
Most of the studies (9/12) were at high risk of bias in at least one of the seven domains assessed. Common problems were unclear
reporting of study methods and lack of blinding. The main limitations in the overall quality of the evidence were high risk of bias and
serious imprecision.
For the analyses of live birth and clinical pregnancy, there was considerable heterogeneity (I2 greater than 75%) and we did not undertake
a meta-analysis. Exploration for the sources of heterogeneity identified two key pre-specified variables as important determinants: stage
of ET (cleavage versus blastocyst stage) and dose of IC-hCG (less than 500 international units (IU) versus 500 IU or greater). We then
performed meta-analysis for these analyses within the subgroups defined by stage of embryo and dose of IC-hCG.
There was an increase in live birth rate in the subgroup of women having cleavage-stage ETs with an IC-hCG dose of 500 IU or greater
compared to women having cleavage-stage ETs with no IC-hCG (risk ratio (RR) 1.57, 95% confidence interval (CI) 1.32 to 1.87,
three RCTs, n = 914, I2 = 0%, moderate quality evidence). In a clinic with a live birth rate of 25% per cycle then the use of IC-hCG -
500 IU or greater would be associated with a live birth rate that varies from 33% to 46%. We did not observe a significant effect on
live birth in any of the other subgroups.
The was an increase in clinical pregnancy rate in the subgroup of women having cleavage-stage ETs with an IC-hCG dose of 500 IU
or greater compared to women having cleavage-stage ETs with no IC-hCG (RR 1.41, 95% CI 1.25 to 1.58, seven RCTs, n = 1414, I2
= 0%, moderate quality evidence). We did not observe a significant effect on clinical pregnancy in either of the other subgroups.
There was no evidence that miscarriage was influenced by intrauterine hCG administration (RR 1.09, 95% CI 0.83 to 1.43, seven
RCTs, n = 3395, I2 = 0%, very low quality evidence).
Other complications reported in the included studies were ectopic pregnancy (three RCTs, n = 915, three events overall), heterotopic
pregnancy (one RCT, n = 495, one event), intrauterine death (two RCTs, n = 978, 21 events) and triplets (one RCT, n = 48, three
events). There was no evidence of a difference between the groups, but there were too few events to allow any conclusions to be drawn
and the evidence was very low quality.
Authors’ conclusions
The pregnancy outcome for cleavage-stage ETs using an IC-hCG dose of 500 IU or greater is promising. However, given the small size
and the variable quality of the trials and the fact that the positive finding was from a subgroup analysis, the current evidence for IC-
hCG treatment does not support its use in assisted reproduction cycles. A definitive large clinical trial with live birth as the primary
outcome is recommended. There was no evidence that miscarriage was influenced by intrauterine hCG administration, irrespective
of embryo stage at transfer or dose of IC-hCG. There were too few events to allow any conclusions to be drawn with regard to other
complications.
P L A I N L A N G U A G E S U M M A R Y
The effect of administering pregnancy hormone in the womb of subfertile women undergoing assisted reproduction
Review question
Does administering pregnancy hormone into the womb of subfertile women undergoing assisted reproduction have any benefit?
Background
Subfertility affects 15% of couples and represents the inability to conceive (become pregnant) naturally following 12 months of regular
unprotected sexual intercourse. Assisted reproduction refers to procedures involving handling of both sperm and eggs in the laboratory in
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a petri dish to create embryos that will be transferred into the womb (embryo transfer (ET)). It is a key option formany subfertile couples
who want to have a baby. Most women undergoing assisted reproduction treatment will reach the stage of ET but the proportion of
embryos that survive following ET has remained small since the mid-1990s. The pregnancy hormone (human chorionic gonadotropin)
is released by the embryo and has an important role in the early stages of pregnancy. Administering natural or synthetic pregnancy
hormone in the womb of subfertile women undergoing assisted reproduction treatment is a novel approach that has been suggested to
increase the chance of having a baby.
Study characteristics
Cochrane authors performed a comprehensive literature search of the standard medical databases (from inception to 10 November
2015) in consultation with the Cochrane Gynaecology and Fertility Group Trials Search Co-ordinator, for all randomised studies
(clinical studies where people are randomly put into one of two or more treatment groups) investigating the effect of administering
pregnancy hormone in the womb of subfertile women undergoing assisted reproduction. Searches and inclusion were irrespective of
language and country of origin. Two authors independently selected studies, evaluated them, extracted data and attempted to contact
the authors where data were missing.
We found 12 studies (4038women) thatmet our inclusion requirements. The natural or synthetic pregnancy hormonewas administered
in variable doses at different times before the ET.
Key results
There was an increase in live birth rate in a post-hoc analysis (after the study was finished) of a subgroup of women having day three
ETs with a pregnancy hormone dose of 500 IU or greater compared to women having day three ETs without pregnancy hormone
(moderate quality evidence from three studies involving 914 women). In a clinic with a live birth rate of 25% per cycle then the use of
a pregnancy hormone dose of 500 IU or greater would be associated with a live birth rate that varies from 33% to 46%. There was no
significant effect on live birth in any of the other subgroups (e.g. lower doses of pregnancy hormone).
Miscarriage was not influenced by administration of pregnancy hormone into the womb, irrespective of embryo stage at transfer or
dose of pregnancy hormone (very low quality evidence from seven studies involving 3395 women). Other complications reported in
the included studies were ectopic pregnancy (where the embryo develops outside the womb), heterotopic pregnancy (where embryos
develop inside and outside the womb), death of embryo while in the womb and triplets. There was no evidence of a difference between
the groups, but there were too few events to allow any conclusions to be drawn and the evidence was very low quality.
The pregnancy outcome for day three ETs using a pregnancy hormone dose of 500 IU or greater is promising. However, given the
small size and the variable quality of the studies and the fact that the positive finding was from only the 500 IU or greater group, the
current evidence for pregnancy hormone treatment does not support its use in assisted reproduction cycles. A definitive large study
with live birth as the primary outcome of interest is recommended.
Quality of the evidence
The evidence was of very low to moderate quality.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Intrauterine administration of hCG for women undergoing assisted reproduction
Population: women undergoing assisted reproduct ion
Settings: assisted reproduct ion units
Intervention: intrauterine administrat ion of hCG
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Control Intrauterine administration
of hCG
Live birth - cleavage stage:
hCG < 500 IU
RR
Follow-up: mean 40 weeks
495 per 1000 376 per 1000
(287 to 500)
RR 0.76
(0.58 to 1.01)
280
(1 study)
⊕©©©
very low1,2
Live birth - cleavage stage:
hCG≥ 500 IU
RR
Follow-up: mean 40 weeks
247 per 1000 388 per 1000
(326 to 462)
RR 1.57
(1.32 to 1.87)
914
(3 studies)
⊕⊕⊕©
moderate3
Live birth - blastocyst
stage: hCG≥ 500 IU
RR
Follow-up: mean 40 weeks
366 per 1000 337 per 1000
(293 to 381)
RR 0.92
(0.80 to 1.04)
1666
(2 studies)
⊕⊕⊕©
moderate3
Pregnancy - cleavage
stage: hCG < 500 IU
RR
Follow-up: mean 12 weeks
579 per 1000 509 per 1000
(405 to 637)
RR 0.88
(0.70 to 1.10)
280
(1 study)
⊕©©©
very low2,3,4
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Pregnancy - cleavage
stage: hCG≥ 500 IU
RR
Follow-up: mean 12 weeks
321 per 1000 453 per 1000
(401 to 507)
RR 1.41
(1.25 to 1.58)
1414
(7 studies)
⊕⊕⊕©
moderate3
Pregnancy - blastocyst
stage: hCG≥ 500 IU
RR
Follow-up: mean 12 weeks
430 per 1000 408 per 1000
(370 to 455)
RR 0.95
(0.86 to 1.06)
1991
(3 studies)
⊕⊕⊕©
moderate3
M iscarriage
Follow-up: mean 40 weeks
48 per 1000 52 per 1000
(40 to 68)
RR 1.09
(0.83 to 1.43)
3395
(7 studies)
⊕©©©
very low2,3,4
Other complications Other complicat ions reported in the included studies were ectopic pregnancy (3 studies, n = 915, 3 events overall)
, heterotopic pregnancy (1 study, n = 495, 1 event), intrauterine death (2 studies, n = 978, 21 events) and triplets (1
study, n = 48, 3 events). There were too few events to allow any conclusions to be drawn
⊕©©©
very low2,3,4
* The basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the
comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; hCG: human chorionic gonadotropin; IU: internat ional units; RR: risk rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Downgraded two levels due to very serious risk of bias: lack of blinding of part icipants and personnel, no clear descript ion
of allocat ion concealment and premature term inat ion of the study following interim analysis.
2 Downgraded one level due to imprecision: total number of events was fewer than 300.
3 Downgraded one level due to serious risk of bias: lack of blinding of part icipants and personnel, no allocat ion concealment.
4 Downgraded two levels due to very serious imprecision: total number of events was fewer than 300 and 95% conf idence
interval around the pooled ef fect includes both no ef fect and appreciable benef it or appreciable harm.
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B A C K G R O U N D
Description of the condition
Subfertility is defined as the inability of a couple to conceive
spontaneously following 12 months of regular unprotected sexual
intercourse. It is estimated that 15% of couples are affected by
subfertility of different causes (female factor, male factor, unex-
plained). Assisted reproduction refers to procedures involving the
in vitro (in a laboratory dish) handling of both human gametes
(sperm and eggs) with the objective of establishing a pregnancy
(Zegers-Hochschild 2009). The most vulnerable step of assisted
reproduction is the embryo transfer (ET) as it involves a radical
change in the embryo’s environment, which makes it prone to
demise (Schoolcraft 2001). Most women undergoing assisted re-
production treatment will reach the stage of ET due to impor-
tant improvements in ovarian stimulation protocols and labora-
tory technology but the proportion of embryos that successfully
implant following ET has remained small (less than one third)
since the mid-1990s (Kupka 2014).
The process of implantation involves a reciprocal interaction be-
tween the embryo and endometrium, culminating in a small re-
ception-ready phase of the endometrium during which implan-
tation can occur. This interaction is dependent on the temporal
differentiation of endometrial cells to attain uterine receptivity.
Implantation failure is thought to occur as a consequence of im-
pairment of the embryo developmental potential or impairment
of uterine receptivity, or both, and the embryo-uterine dialogue
(Diedrich 2007).
Many interventions have been attempted, with varying degrees
of success, before ET (endometrial injury (Nastri 2012), dummy
ET (Mansour 1990), endometrial preparation (Derks 2009), peri-
implantation (heparin (Akhtar 2013), aspirin (Siristatidis 2011)),
during ET (ultrasound guidance (Brown 2010), cervical mucous
removal (Craciunas 2014)), and after ET (fibrin sealant, bed rest
(Abou-Setta 2014)) in order to optimise the embryo-endometrial
interaction and improve outcomes.
Description of the intervention
Human chorionic gonadotropin (hCG) is a hormone synthesised
and released by the syncytiotrophoblast. It stimulates ovarian pro-
duction of progesterone during the first trimester of pregnancy.
Intrauterine administration of synthetic or natural hCG around
the time of ET is a novel approach that has been suggested to
improve the outcomes of assisted reproduction treatment based
on the fundamental role of hCG in embryo implantation and the
early stages of pregnancy (Cole 2010). The intervention involves
the intrauterine administration of hCG via an ET catheter dur-
ing a mock procedure (a trial of the actual ET without using an
embryo, performed to assess the difficulty of the ET) using the
lowest volume of medium before the conventional ET. The hCG
can be released in different points inside the uterine cavity (close
to the internal cervical os, mid-cavity or near the fundus) within
minutes, hours or days before the actual ET. The hCG sources for
medical treatments include extraction from the urine of pregnant
women (natural) or from cell cultures using recombinant DNA
technology (rhCG).
How the intervention might work
The hCG may promote peritrophoblastic immune tolerance,
which facilitates trophoblast invasion by inducing an increase in
endometrial T-cell apoptosis (Kayisli 2003). It also supports tro-
phoblast apposition (the first stage of implantation, loose align-
ment of the trophoblast to the decidua) and adhesion (second stage
of implantation, closer attachment of the trophoblast to the de-
cidua) to the endometrium by regulating proteins involved in im-
plantation (Racicot 2014). Intrauterine injection of urinary hCG
alters endometrial secretory parameters (Licht 1998), while cell
proliferation and migration are increased in the presence of hCG
(Bourdiec 2013).
Why it is important to do this review
Subfertility affects a relatively large proportion of couples and as-
sisted reproduction treatments remain costly and stressful. All the
effort should be directed towards increasing the success rates of in-
fertility treatment and primary research should be translated into
clinical practice in an efficient and timely manner. Intrauterine
administration of hCG around the time of ET has the potential
to improve the outcome of assisted reproduction treatments and
randomised and non-randomised trials have reported varying re-
sults (Mansour 2011; Rebolloso 2013).
One meta-analysis assessed the efficacy of intrauterine injection of
hCG before ET in assisted reproductive cycles, but improvements
could be made to the methods of analysis (Ye 2015). Different
studies have evaluated variable circumstances of intrauterine hCG
administration in terms of stage of the embryo at transfer (cleav-
age versus blastocyst), source of hCG (urine versus recombinant),
dose of hCG, embryo processing (fresh versus frozen-thawed) and
number of embryos transferred, leading to real uncertainties about
the role of the intervention.
O B J E C T I V E S
To investigate whether the intrauterine administration of hCG
around the time of ET improves the clinical outcomes in subfertile
women undergoing assisted reproduction.
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M E T H O D S
Criteria for considering studies for this review
Types of studies
We included all randomised controlled trials (RCTs) evaluating
intrauterine administration of hCG around the time of ET in this
review irrespective of language and country of origin. We planned
to include only data from the first phase of cross-over RCTs in
meta-analyses.
Types of participants
Subfertile women undergoing in vitro fertilisation (IVF)/intracy-
toplasmic sperm injection (ICSI) followed by ET.
Types of interventions
RCTs comparing intrauterine administration of hCG around the
time of ET versus any other active intervention, no intervention
or placebo were eligible for inclusion.
Types of outcome measures
Primary outcomes
• Live birth (the delivery of a live foetus after 24 completed
weeks of gestational age) rate per woman or couple randomised.
• Miscarriage (the loss of the pregnancy before 24 completed
weeks of gestational age) rate per woman or couple randomised.
Secondary outcomes
• Clinical pregnancy (the presence of a gestational sac on
ultrasound scan) rate per woman or couple randomised.
• Complication rate per woman or couple randomised,
including ectopic pregnancy, intrauterine growth restriction,
foetal or congenital defects, pelvic infection or other adverse
events, reported as an overall complication rate or as individual
outcomes, or both (as reported by individual studies).
Search methods for identification of studies
We sought all published and unpublished RCTs of intrauter-
ine hCG administration around the time of ET in consultation
with the Cochrane Gynaecology and Fertility Group Trials Search
Co-ordinator. The search dates were from the inception of the
databases to 10 November 2015 without any language restriction.
Electronic searches
We combined the MEDLINE search with the Cochrane highly
sensitive search strategy for identifying RCTs, which appears in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011, Chapter 6, Section 6.4.11). We combined the EMBASE
and CINAHL searches with trial filters developed by the Scot-
tish Intercollegiate Guidelines Network (SIGN) (www.sign.ac.uk/
methodology/filters.html#random).
The search terms used for theCochrane Gynaecology and Fertility
Group Specialised Register, Cochrane Central Register of Con-
trolled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL
and PsycINFO are presented in the Appendices (Appendix 1;
Appendix 2; Appendix 3; Appendix 4; Appendix 5; Appendix 6).
We searched the World Health Organization International
Clinical Trials Registry Platform (apps.who.int/trialsearch/
Default.aspx) and ClinicalTrials.gov for ongoing and registered
trials. We searched OpenGrey (www.opengrey.eu/) and Google
Scholar (scholar.google.co.uk/) for grey literature. We hand-
searched the abstracts published following major conferences (e.g.
the American Society for Reproductive Medicine (ASRM), Euro-
peanSociety ofHumanReproduction andEmbryology (ESHRE))
in the last five years to find additional studies not yet published in
full.
Searching other resources
We screened the references lists of all included studies and relevant
reviews to identify further articles for possible inclusion.
Data collection and analysis
WeusedReviewManager 5 for input of data and statistical analysis
(RevMan 2012), in accordance with the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011).
Selection of studies
Two authors (LC and NT) independently screened the title, ab-
stract and keywords for each publication to exclude the studies
that were irrelevant for the objective of this review. We retrieved
the remaining publications in full text and the same two authors
appraised them independently to identify the RCTs suitable for
inclusion. There was no disagreement related to study eligibility.
We documented the selection process with a PRISMA flow chart.
Data extraction and management
Two authors (LC and NT) independently extracted data using
a pre-designed and pilot-tested data extraction form. For stud-
ies with multiple publications, we used the main RCT report as
the reference and we supplemented it with additional data from
secondary publications. We attempted to contact authors where
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published data were insufficient. There were no disagreements.
One author (LC) entered data into Review Manager 5 (RevMan
2012), and a second author (NT) checked the data against the
data extraction form.
Assessment of risk of bias in included studies
We used the Cochrane ’Risk of bias’ assessment tool to assess the
included studies for: selection, performance, detection, attrition,
reporting and other bias. There were no disagreements. We in-
cluded the ’Risk of bias’ table in the ’Characteristics of included
studies’ table, describing the judgements in detail.
Measures of treatment effect
All outcomes were dichotomous. We calculated Mantel-Haenszel
risk ratios (RRs) with 95% confidence intervals (CI) using the
numbers of events in the intervention and control groups of each
study. For outcomes with event rates below 1%, we used the Peto
one-step odds ratio (OR) method to calculate the combined out-
come with 95% CI.
Unit of analysis issues
We performed analysis per woman or couple randomised for live
birth, clinical pregnancy, miscarriage and complication rates. We
counted multiple live births (twins, triplets) as a single live birth
event.We performed a secondary analysis for miscarriage per clin-
ical pregnancy to broaden the understanding of the treatment ef-
fect.
If a study included multiple treatment arms based on hCG dose,
we planned to split the control group proportionally with the ex-
perimental groups in order to avoid analysing control participants
in duplicate.
Dealing with missing data
We attempted to contact the authors of the RCTs to obtainmissing
data in order to perform analyses on an intention-to-treat basis. In
the case of unobtainable data, we planned imputationof individual
values to be undertaken for the live birth rate only. We assumed
that live births had not occurred in participants without a reported
outcome. For other outcomes, we analysed only the available data.
Assessment of heterogeneity
We identified heterogeneity by visual inspection of forest plots and
by using a standard Chi2 test with significance set at P value <
0.1. We used the I2 statistic to estimate the total variation across
RCTs that was due to heterogeneity, where I2 greater than 50%
indicated substantial heterogeneity.
Assessment of reporting biases
We conducted a comprehensive search to minimise the potential
impact of publication bias and other reporting biases. We planned
to use a funnel plot to explore the possibility of small-study effects
when the number of included RCTs exceeded 10.
Data synthesis
We combined the data from similar RCTs comparing similar treat-
ments using a random-effects model. We displayed an increase
in the odds of an outcome to the right of the centre line and a
decrease in the odds of an outcome to the left of the centre line.
For comparisons where there was considerable clinical, method-
ological or statistical heterogeneity (I2 greater than 75%), we did
not combine RCTs results in a meta-analysis. Where data were in-
complete and could not be presented in the analyses, we reported
available data in narrative form.
Subgroup analysis and investigation of heterogeneity
Where data were available, we conducted subgroup analyses to
investigate the efficacy of intrauterine hCGadministration around
the time of ET depending on:
• stage of the embryo at transfer (cleavage versus blastocyst);
• source of intra-cavity hCG (IC-hCG) (urine versus
recombinant);
• embryo processing (fresh versus frozen-thawed);
• number of embryos transferred.
If we detected substantial heterogeneity, we explored possible
explanations in sensitivity analyses. Factors considered included
treatment indication, age of the women, ovarian stimulation pro-
tocol, response to ovarian stimulation, timing of IC-hCG admin-
istration, IC-hCG dose and volume of infused medium, method
of IC-hCG administration (i.e. type of catheter), embryo quality,
endometrial thickness, source of oocytes (i.e. donated, own) and
ET difficulty. We took any statistical heterogeneity into account
when interpreting the results, especially if there was any variation
in the direction of effect.
Sensitivity analysis
We performed sensitivity analysis to examine the stability and
robustness of the results for the primary outcomes in relation to
the following eligibility and analysis factors.
• Inclusion of RCTs without high risk of bias.
• Publication type (abstract versus full text).
• Use of a random-effects model.
• Calculation of OR.
• Imputation of outcomes.
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Overall quality of the body of evidence: ’Summary of
findings’ table
Weprepared a ’Summary of findings’ table using GRADEpro soft-
ware. This table evaluated the overall quality of the body of evi-
dence for the main review outcomes (live birth rate, miscarriage
and clinical pregnancy rate) using GRADE criteria (study limi-
tations (i.e. risk of bias), consistency of effect, imprecision, indi-
rectness and publication bias). We justified, documented and in-
corporated judgements about evidence quality (high, moderate or
low) into reporting of results for each outcome.
R E S U L T S
Description of studies
Results of the search
We performed the systematic search on 10 November 2015 and
identified 516 publications (499 fromdatabases and 17 fromother
sources). Nineteen articles were potentially relevant and we as-
sessed these in full text. We included 12 articles, excluded five ar-
ticles and two articles await classification. See Figure 1 for detailed
search results.
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Figure 1. Study flow diagram.
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Included studies
Types of studies
All 12 included studies were parallel-arm RCTs. One study had
two experimental arms (IC-hCG 500 IU versus IC-hCG 1000 IU
versus control) (Janati 2013), one study had two phases with three
experimental arms (phase one: IC-hCG 100 IU versus IC-hCG
200 IU versus control; and phase two: IC-hCG 500 IU versus
control) (Mansour 2011), and one study had two experimental
arms at two different timings (IC-hCG 500 IU versus control
two days prior to ET; IC-hCG 500 IU versus control on the day
of ET) (Wirleitner 2015a). Six studies were as full text articles
(Aaleyasin 2015; Hong 2014; Mansour 2011; Santibañez 2014;
Wirleitner 2015a; Zarei 2014), and six studies were abstracts (
Cambiaghi 2013; Janati 2013; Kokkali 2014; Leao 2013; Singh
2014; Wirleitner 2015b).
Six studies did not report funding (Aaleyasin 2015; Cambiaghi
2013; Hong 2014; Janati 2013; Leao 2013; Wirleitner 2015a),
and six studies reported internal funding (Kokkali 2014;Mansour
2011; Santibañez 2014; Singh 2014; Wirleitner 2015b; Zarei
2014). None of the studies reported external funding.
Participants
Participants were couples/women recruited prior to undergoing
assisted reproductive treatment for different subfertility causes.
The number of participants varied between 36 (Leao 2013) and
1186 (Wirleitner 2015a). The studies were conducted in Iran,
Brazil, USA, Greece, Egypt, Mexico, India and Austria.
Interventions
Most of the studies compared intrauterine administration of urine
hCG 500 IU with controls. One study had two additional arms
with lower doses (IC-hCG 100 and 200 IU) (Mansour 2011), and
one study had an additional arm with higher dose (IC-hCG 1000
IU) (Janati 2013). One study used rhCG 250 µg (equivalent of
6500 IU) (Zarei 2014), and one study used intra-cavity rhCG (IC-
rhCG) 40 µL (equivalent to 500 IU) (Singh 2014).
Nine studies administered the IC-hCGwithinminutes before ET (
Aaleyasin 2015;Hong 2014; Janati 2013; Kokkali 2014;Mansour
2011; Santibañez 2014; Singh 2014; Wirleitner 2015b; Zarei
2014), ranging from less than three minutes (Hong 2014) up to
12 minutes (Zarei 2014), and two studies administered the IC-
hCG six hours before ET (Cambiaghi 2013; Leao 2013). One
study had four groups (two experimental and two controls) at two
different timings (two days before ET and three minutes before
ET) (Wirleitner 2015a).
For the control groups, six studies administered the same volume of
transfermedia (Hong 2014), culturemedia (Aaleyasin 2015; Singh
2014; Wirleitner 2015a; Wirleitner 2015b), or normal saline (
Zarei 2014), without hCG and six studies did not administer
anything prior to ET (Cambiaghi 2013; Janati 2013; Kokkali
2014; Leao 2013; Mansour 2011; Santibañez 2014).
Outcomes
Seven studies reported on one of our pre-defined primary out-
comes: live birth (Aaleyasin 2015; Mansour 2011; Singh 2014;
Wirleitner 2015a; Wirleitner 2015b) and miscarriage (Aaleyasin
2015; Hong 2014; Janati 2013; Mansour 2011; Singh 2014;
Wirleitner 2015a; Wirleitner 2015b).
Twelve studies reported on one of our pre-defined secondary
outcomes: clinical pregnancy (Aaleyasin 2015; Cambiaghi 2013;
Hong 2014; Janati 2013; Kokkali 2014; Leao 2013; Mansour
2011; Santibañez 2014; Singh 2014;Wirleitner 2015a;Wirleitner
2015b; Zarei 2014), and complications (Aaleyasin 2015;Mansour
2011; Santibañez 2014; Zarei 2014).
Studies awaiting classification
Two studies await classification (Badehnoosh 2014; Bhat 2014).
These studies reported interim outcomes (implantation rate and
fertilisation rate) and it was unclear whether they also collected
data on clinical outcomes that might be relevant to our review. We
emailed the authors of these studies in February 2016, asking for
more information on the methods and outcome measures of their
studies.
Excluded studies
We excluded five studies due to retrospective design (Jeong 2013),
non-randomisation (Li 2013; Rebolloso 2013; Riboldi 2013), and
meta-analysis (Ye 2015).
Risk of bias in included studies
Figure 2 shows the ’Risk of bias’ graph and Figure 3 shows the
’Risk of bias’. See the Characteristics of included studies table for
rationales behind each judgement.
11Intrauterine administration of human chorionic gonadotropin (hCG) for subfertile women undergoing assisted reproduction (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Sequence generation
All included studies were RCTs. The randomisation techniquewas
adequate in 10 studies (Aaleyasin 2015; Cambiaghi 2013; Hong
2014; Janati 2013; Kokkali 2014; Mansour 2011; Santibañez
2014; Singh 2014; Wirleitner 2015a; Zarei 2014), which we clas-
sified at low risk of bias. Two studies lacked adequate randomi-
sation description and we classified them at unclear risk of bias
(Leao 2013; Wirleitner 2015b).
Allocation concealment
Three studies mentioned adequate allocation concealment and
we classified them at low risk of bias (Aaleyasin 2015; Hong
2014; Kokkali 2014). Nine studies lacked a description of meth-
ods of allocation concealment and we classified them at unclear
risk of bias (Cambiaghi 2013; Janati 2013; Leao 2013; Mansour
2011; Santibañez 2014; Singh 2014;Wirleitner 2015a;Wirleitner
2015b; Zarei 2014).
Blinding
Four studies documented blinding of participants or personnel
(or both) and we classified them at low risk of bias (Aaleyasin
2015; Hong 2014; Wirleitner 2015b; Zarei 2014). We classified
the remaining studies at high risk of bias (Cambiaghi 2013; Janati
2013; Kokkali 2014; Leao 2013;Mansour 2011; Santibañez 2014;
Singh 2014; Wirleitner 2015a).
The outcome measurement was not likely to be influenced by lack
of blinding; hence, we classified all studies at low risk of bias.
Incomplete outcome data
Five studies followed up all participants and reported the results
adequately (Aaleyasin 2015; Hong 2014; Santibañez 2014; Singh
2014; Wirleitner 2015b). We classified these at low risk of bias.
We classified six studies at unclear risk of bias (Cambiaghi 2013;
Janati 2013; Kokkali 2014; Leao 2013;Mansour 2011;Wirleitner
2015a). One study reported large numbers of participants lost to
follow-up and we classified this at high risk of bias (Zarei 2014).
Selective reporting
Five studies reported on all relevant outcomes and we classified
them at low risk of bias (Aaleyasin 2015; Mansour 2011; Singh
2014; Wirleitner 2015a; Wirleitner 2015b). All studies reported
on clinical pregnancy, but, if there were no reports on live birth,
we classified them at unclear risk of bias (Cambiaghi 2013; Hong
2014; Janati 2013; Kokkali 2014; Leao 2013; Santibañez 2014;
Zarei 2014).
Other potential sources of bias
We classified six studies at low risk of other potential bias because
groups appeared to be comparable at baseline and we could not
identify any other sources of bias (Aaleyasin 2015; Santibañez
2014; Singh 2014; Wirleitner 2015a; Wirleitner 2015b; Zarei
2014).We classified four studies at unclear risk of bias because they
did not report onbaseline characteristics between groups (probably
due to availability as abstract only) (Cambiaghi 2013; Janati 2013;
Kokkali 2014), or reported a large number of participants who
declined to participate after randomisation for various reasons (
Hong 2014). We classified two studies at high risk of bias due to
lack of reporting of participant numbers in each study group (Leao
2013), and due to performing interim analysis that changed the
study protocol and ended the study prematurely (Mansour 2011)
The overall birth rate in the control groups in Mansour 2011 was
47%, whereas the control group live birth rate ranged from 25%
to 39% in the other included studies. The reason for this was
unclear. The mean age of women in Mansour 2011 was under 30
years, but this was also the case in Aaleyasin 2015, which reported
a control group live birth rate of only 25%.
Effects of interventions
See: Summary of findings for the main comparison
Intrauterine administration of hCG for women undergoing
assisted reproduction
Note: One study included three experimental arms based on in-
trauterine hCG dose and we regarded and analysed them as three
separate comparisons (Mansour 2011).We split the control group
proportionally with the experimental groups in order to avoid
analysing control participants in duplicate. One study investigated
intrauterine hCG administration at two different timings (day
three versus day five administration) and we regarded and analysed
them as two separate comparisons (Wirleitner 2015a).
Two of the comparisons had considerable heterogeneity (I2 greater
than 75%) and we did not perform a global meta-analysis, as pre-
specified in the protocol (Craciunas 2015) (Analysis 1.1; Analysis
1.4).
Exploration for the sources of heterogeneity in these analyses iden-
tified two key pre-specified variables as important determinants:
stage of ET (cleavage versus blastocyst stage) and dose of IC-hCG
(less than 500 IU versus 500 IU or greater). When we subgrouped
the data according to these variables, there was evidence of sig-
nificant differences between the subgroups. We then performed
meta-analysis within the subgroups defined by stage of embryo
and dose of hCG.
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Primary outcomes
Live birth (Analysis 1.1)
Five studies with eight experimental arms reported on live birth
(Aaleyasin 2015; Mansour 2011; Singh 2014; Wirleitner 2015a;
Wirleitner 2015b) (Analysis 1.1).
Subgroup analysis
The forest plot displayed the studies based on the embryo stage at
transfer and the hCGdose (Figure 4). The test for subgroup differ-
ences indicated a considerable difference between the subgroups
(Chi2 = 29.39, degrees of freedom (df ) = 2, P value ≤ 0.00001, I
2 = 92.3%).
• Cleavage stage: IC-hCG less than 500 IU versus no IC-
hCG: one RCT with two experimental arms contributed to the
calculation of the combined outcome (Mansour 2011). The
heterogeneity was insignificant (Chi2 = 0.01, df = 1, P value =
0.91, I2 = 0%) and there was no evidence of a difference between
the groups in live birth rates (RR 0.76, 95% CI 0.58 to 1.01,
one RCT, n = 280, I2 = 0%, very low quality evidence).
• Cleavage stage: IC-hCG 500 IU or greater versus no IC-
hCG: three RCTs contributed to the calculation of the combined
outcome (Aaleyasin 2015; Mansour 2011; Singh 2014). The
heterogeneity was insignificant (Chi2 = 0.59, df = 2, P value =
0.75, I2 = 0%) and the live birth rate was higher in the hCG
group (RR 1.57, 95% CI 1.32 to 1.87, three RCTs, n = 914, I2 =
0%, moderate quality evidence). This suggested that in women
with a 25% chance of live birth without using IC-hCG, the live
birth rate in women using IC-hCG 500 IU or greater will be
between 33% and 46%.
• Blastocyst stage: IC-hCG 500 IU or greater versus no IC-
hCG: two RCTs with three experimental arms contributed to the
calculation of the combined outcome (Wirleitner 2015a;
Wirleitner 2015b). The heterogeneity was insignificant (Chi2 =
0.11, df = 2, P value = 0.95, I2 = 0%) and there was no evidence
of a difference between the groups in live birth rates (RR 0.92,
95% CI 0.80 to 1.04, two RCTs, n = 1666, I2 = 0%, moderate
quality evidence).
Data were insufficient to perform the pre-specified subgroup anal-
yses based on embryo processing and number of embryos trans-
ferred.
Sensitivity analyses
Removing the studieswith high risk of bias in one ormore domains
(Mansour 2011; Singh 2014; Wirleitner 2015a) did not alter the
results significantly, but it meant that there were no data for one
of the comparisons
• cleavage stage: IC-hCG less than 500 IU versus no IC-
hCG: no data
• cleavage stage: IC-hCG 500 IU or greater versus no IC-
hCG: RR 1.65 (95% CI 1.27 to 2.16, one RCT, n=483)
• blastocyst stage: IC-hCG 500 IU or greater versus no IC-
hCG (RR 0.88, 95% CI 0.66 to 1.17, one RCT, n = 480)
Removing the studies available as abstract only (Singh 2014;
Wirleitner 2015b) did not alter the results significantly:
• cleavage stage: IC-hCG less than 500 IU versus no IC-hCG
(RR 0.76, 95% CI 0.58 to 1.01, one RCT, n = 280, I2 = 0%,
very low quality evidence);
• cleavage stage: IC-hCG 500 IU or greater versus no IC-
hCG (RR 1.55, 95% CI 1.28 to 1.87, two RCTs, n = 698, I2 =
0%, moderate quality evidence);
• blastocyst stage: IC-hCG 500 IU or greater versus no IC-
hCG (RR 0.92, 95% CI 0.80 to 1.07, one RCT, n = 1186, I2 =
0%, moderate quality evidence).
The calculated combined outcome using the fixed-effect model
was similar to random-effects model for:
• cleavage stage: IC-hCG less than 500 IU versus no IC-hCG
(RR 0.76, 95% CI 0.58 to 1.01, one RCT, n = 280, I2 = 0%,
very low quality evidence);
• cleavage stage: IC-hCG 500 IU or greater versus no IC-
hCG (RR 1.59, 95% CI 1.33 to 1.90, three RCTs, n = 914, I2 =
0%, moderate quality evidence);
• blastocyst stage: IC-hCG 500 IU or greater versus no IC-
hCG (RR 0.91, 95% CI 0.80 to 1.04, two RCTs, n = 1666, I2 =
0%, moderate quality evidence).
There was no significant difference between OR and RR:
• cleavage stage: IC-hCG less than 500 IU versus no IC-hCG
(OR 0.62, 95% CI 0.38 to 1.03, one RCT, n = 280, I2 = 0%,
very low quality evidence);
• cleavage stage: IC-hCG 500 IU or greater versus no IC-
hCG (OR 2.10, 95% CI 1.59 to 2.79, three RCTs, n = 914, I2 =
0%, moderate quality evidence);
• blastocyst stage: IC-hCG 500 IU or greater versus no IC-
hCG (OR 0.87, 95% CI 0.71 to 1.06, two RCTs, n = 1666, I2 =
0%, moderate quality evidence).
Miscarriage (Analysis 1.2, Figure 5)
Seven studies with 10 experimental arms reported on miscar-
riage (Aaleyasin 2015; Hong 2014; Mansour 2011; Singh 2014;
Wirleitner 2015a; Wirleitner 2015b; Zarei 2014) (Analysis 1.2;
Figure 4). The heterogeneity between the studies was unsubstan-
tial (Chi2 = 4.30, df = 9, P value = 0.89, I2 = 0%) and there was no
evidence of a difference between the groups in miscarriage rates
(RR 1.09, 95% CI 0.83 to 1.43, seven RCTs, n = 3395, I2 = 0%,
very low quality evidence).
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Figure 4. Forest plot of comparison: 1 Intrauterine human chorionic gonadotropin (hCG) versus no hCG,
outcome: 1.2 Miscarriage.
One study investigated IC-hCG500 IUand 1000 IUand reported
similarmiscarriage rates between experimental and control groups,
without providing sufficient data to be included in a meta-analysis
(Janati 2013).
Sensitivity analyses
Removing the studieswith high risk of bias in one ormore domains
(Mansour 2011; Singh 2014; Wirleitner 2015a) did not alter the
results significantly (RR 1.25 [0.84, 1.87, four studies, n=1498, I
2=0%)
Removing the two studies available as abstract only (Singh 2014;
Wirleitner 2015b) did not alter the results significantly (RR 1.09,
95% CI 0.80 to 1.48, five RCTs, n = 2699, I2 = 0%, very low
quality evidence).
The calculated combined outcome using the fixed-effect model
was similar to that of the random-effects model (RR 1.10, 95%
CI 0.84 to 1.44, seven RCTs, n = 3395, I2 = 0%, very low quality
evidence).
There was no significant difference between OR and RR (OR
1.09, 95% CI 0.82 to 1.46, seven RCTs, n = 3395, I2 = 0%, very
low quality evidence).
Secondary analysis per clinical pregnancy (Analysis 1.3)
There was no evidence of a difference between the groups in mis-
carriage rates calculated per clinical pregnancy (RR 1.00, 95% CI
0.77 to 1.30, seven RCTs, n = 1450, I2 = 0%, very low quality
evidence) (Analysis 1.3).
Secondary outcomes
Clinical pregnancy (Analysis 1.4)
All included studies reported clinical pregnancy (Analysis 1.4).
Subgroup analysis
The forest plot displayed the studies based on the embryo stage
at transfer and the hCG dose (Figure 5). The test for subgroup
differences indicated a considerable difference between the sub-
groups (Chi2 = 28.83, df = 2, P value ≤ 0.00001, I2 = 93.1%).
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Figure 5. Forest plot of comparison: 1 Intrauterine human chorionic gonadotropin (hCG) versus no hCG,
outcome: 1.4 Clinical pregnancy.
• Cleavage stage: IC-hCG less than 500 IU versus no IC-
hCG: one RCT with two experimental arms contributed to the
calculation of the combined outcome (Mansour 2011). The
heterogeneity was insignificant (Chi2 = 0.07, df = 1, P value =
0.80, I2 = 0%) and there was no evidence of a difference between
the groups in clinical pregnancy rates (RR 0.88, 95% CI 0.70 to
1.10, one RCT, n = 280, I2 = 0%, very low quality evidence).
• Cleavage stage: IC-hCG 500 IU or greater versus no IC-
hCG: seven RCTs contributed to the calculation of the
combined outcome (Aaleyasin 2015; Cambiaghi 2013; Leao
2013; Mansour 2011; Santibañez 2014; Singh 2014; Zarei
2014). The heterogeneity was insignificant (Chi2 = 3.18, df = 6,
P value = 0.79, I2 = 0%) and the clinical pregnancy rate was
higher in the hCG group (RR 1.41, 95% CI 1.25 to 1.58, seven
RCTs, n = 1414, I2 = 0%, moderate quality evidence).
One study investigated IC-hCG500 IUand 1000 IUand reported
similar clinical pregnancy rates between experimental and control
groups (Janati 2013). One study investigated IC-hCG500 IU and
reported no evidence of a difference between the groups in clinical
pregnancy rates (Kokkali 2014). Data from these two studies were
insufficient to be included in meta-analysis.
• Blastocyst stage: IC-hCG 500 IU or greater versus no IC-
hCG: three RCTs with four experimental arms contributed to
the calculation of the combined outcome (Hong 2014;
Wirleitner 2015a; Wirleitner 2015b). The heterogeneity was
insignificant (Chi2 = 2.91, df = 3, P value = 0.41, I2 = 0%) and
there was no evidence of a difference between the groups in
clinical pregnancy rates (RR 0.95, 95% CI 0.86 to 1.06, three
RCTs, n = 1991, I2 = 0%, moderate quality evidence).
Data were insufficient to perform the pre-defined subgroup anal-
yses based on embryo processing and number of embryos trans-
ferred.
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Complications (Analysis 1.5)
Four studies with six experimental arms reported complications
(Aaleyasin 2015; Mansour 2011; Santibañez 2014; Zarei 2014)
(Analysis 1.5).
None of the studies found evidence of a difference between the
groups for any of thementioned complications: ectopic pregnancy
(three studies, n =915, three events overall), heterotopic pregnancy
(one study, n = 495, one event), intrauterine death (two studies,
n = 978, 21 events), triplets (one study, n = 48, three events). For
intrauterine death, the analysis in Figure 6 displays the Peto OR
(which is the default setting for this analysis). Mantel-Haenszel
random-effects RRs were almost identical (RR 0.82, 95% CI 0.34
to 1.94, two studies, n = 978, I2 = 0%).
Figure 6. Forest plot of comparison: 1 Intrauterine human chorionic gonadotropin (hCG) versus no hCG,
outcome: 1.5 Complications: intrauterine death.
D I S C U S S I O N
Summary of main results
This systematic review included 12 RCTs investigating the effect
of intrauterine administration of hCG for 4038 subfertile women
undergoing assisted reproduction. The IC-hCG was administered
in variable doses at different timings before the ET. The source of
hCG was from the urine of pregnant women or from cell cultures
using recombinant DNA technology.
Due to considerable heterogeneity (I2 greater than75%) for several
of the comparisons, we did not perform a global meta-analysis, as
pre-specified in the protocol (Craciunas 2015). Exploration for the
sources of heterogeneity identified two key pre-specified variables
as important determinants: stage of ET (cleavage versus blastocyst
stage) and dose of IC-hCG (less than 500 IU versus 500 IU or
greater). We then performed meta-analysis within the subgroups
defined by stage of embryo and dose of IC-hCG.
There was an increase in live birth rate in the subgroup of women
having cleavage-stage ETs with an IC-hCG dose of 500 IU or
greater compared to women having cleavage-stage ETs with no
IC-hCG. There was no significant effect on live birth in any of
the other subgroups.
There was an increase in clinical pregnancy rate in the subgroup
of women having cleavage-stage ETs with an IC-hCG dose of 500
IU or greater compared to women having cleavage-stage ETs with
no IC-hCG. There was no significant effect on clinical pregnancy
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rate in any of the other subgroups.
There was no evidence that miscarriage and complication rates
were influenced by IC-hCG administration, irrespective of em-
bryo stage at transfer or dose of IC-hCG.
Overall completeness and applicability of
evidence
All RCTs reported on clinical pregnancy, which is an important
secondary outcome, but only a few RCTs continued the follow-
up until live birth, which is the most important primary outcome.
Most RCTs reportedmiscarriage rates. RCTs rarely reported com-
plications and adverse events, or their absence.
Data were insufficient to perform all the planned subgroup anal-
yses.
The inclusion criteria for participants assured a broad range of
subfertility causes and women’s characteristics similar to what is
expected in a regular assisted reproduction unit.
Quality of the evidence
Weratedmost of the studies (9/12) at high risk of bias in at least one
of the seven domains assessed. Common problems were unclear
reporting of study methods and lack of blinding. Brief reporting
of results in studies published as abstracts represent additional
potential sources of bias. Six studies did not report funding and
six studies reported internal funding. None of the studies reported
external funding.
The quality of the evidence as assessed using GRADE was moder-
ate for live birth and clinical pregnancy, which means that further
research is likely to have an important impact on our confidence
in the estimate of effect and may change the estimate. The quality
of the evidence for miscarriage was very low, meaning that we are
very uncertain about the estimate. The main limitations in the
overall quality of the evidence were high risk of bias and serious
imprecision.
Potential biases in the review process
We performed a systematic search in consultation with the
Cochrane Gynaecology and Fertility Group Trials Search Co-or-
dinator, but we cannot be sure all relevant trials were identified for
inclusion. The protocol was pre-published and followed accord-
ingly (Craciunas 2015). We attempted to contact authors when
data were missing, but only one author replied providing clarifica-
tion and additional data (Mansour 2011). We performed analyses
on an intention-to-treat basis. Potential bias in the review process
was unlikely.
Agreements and disagreements with other
studies or reviews
One previously published meta-analysis concluded that women
undergoing IVF/ICSI may benefit from IC-hCG injection before
ET (Ye 2015).
The reported effect of intrauterine hCG administration was con-
sistent within the subgroups of our review, with an apparent dif-
ferent effect based on the stage of embryo at transfer and dose of
IC-hCG.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The pregnancy outcome for cleavage-stage transfers using an in-
tra-cavity human chorionic gonadotropin (IC-hCG) dose of 500
IU or greater is promising. However, given the small size and the
variable quality of the trials and the fact that the positive finding
was from a subgroup analysis, the current evidence for IC-hCG
treatment does not support its use in an assisted reproduction cy-
cle. There was no evidence that miscarriage was influenced by in-
trauterine human chorionic gonadotropin (hCG) administration,
irrespective of embryo stage at transfer or dose of IC-hCG. There
were too few events to allow any conclusions to be drawn with
regard to other complications.
Implications for research
The findings of this review should be a strong foundation for
funding and conducting a definitive high-quality randomised con-
trolled trial of intrauterine hCG administration for women under-
going assisted reproduction according to theCONSORT(Consol-
idated Standards of Reporting Trials) guidelines. It should be pow-
ered adequately and it should focus on subgroup analysis (cleavage
versus blastocyst, fresh versus frozen-thawed, single versus two or
more embryo transfers, cause of subfertility) in order to identify
the groups of women who would benefit the most from this in-
tervention and it should report on potential adverse events. Live
birth rate must be the primary outcome.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aaleyasin 2015
Methods Design: 2-armed parallel RCT
Location: Shariati Teaching Hospital, Tehran, Iran
Period: January 2011 to July 2012
Power calculation: yes
Funding: not mentioned
Trial registration: not mentioned and not found
Publication type: full text
Participants Number: 483
Women’s age (mean years; experimental vs. control): 29.1 vs. 28.7
Inclusion criteria: all infertile women who were candidates for the first IVF/ICSI
Exclusion criteria: aged > 40 years, history of percutaneous epididymal sperm aspiration,
testicular sperm extraction, myomectomy, hydrosalpinx, presence of uterine fibroma
with the pressure effect on endometrium, endometriosis, and azoospermia
Ovarian controlled hyperstimulation: long GnRH agonist protocol
Fertilisation: ICSI
Stage of the embryo at transfer: cleavage
Embryo processing: fresh
Number of embryos transferred (mean; experimental vs. control): 2.8 vs. 2.9
Interventions Experimental: hCG 500 IU in a volume of 50 µL tissue culture media (Vitrolife,
Göteborg, Sweden) was injected into the uterus 5-7 minutes prior to ET
Control: 50 µL tissue culture media (Vitrolife, Göteborg, Sweden) instead of hCG
Outcomes Clinical pregnancy, miscarriage, live birth, intrauterine death
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated list
Allocation concealment (selection bias) Low risk A technician, not belonging to the study
personnel, prepared and coded the drugs
according to the list
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk All participants and clinical care providers
were blinded to the list until the end of the
study
23Intrauterine administration of human chorionic gonadotropin (hCG) for subfertile women undergoing assisted reproduction (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Aaleyasin 2015 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All participants and clinical care providers
were blinded to the list until the end of the
study
Incomplete outcome data (attrition bias)
All outcomes
Low risk 0 women lost to follow-up
Selective reporting (reporting bias) Low risk Reported on all important outcomes
Other bias Low risk Similar baseline characteristics between
groups after randomisation
Cambiaghi 2013
Methods Design: 2-armed parallel RCT
Location: Instituto Paulista de Ginecologia, Obstetricia e Medicinada Reproducao, Sao
Paulo, Brazil
Period: January to December 2012
Power calculation: no
Funding: not mentioned
Trial registration: not mentioned and not found
Publication type: abstract
Participants Number: 44
Women’s age (mean years; experimental vs. control): not mentioned
Inclusion criteria: endometrial thickness > 7 mm on the day that the donor received
hCG and at least 2 blastocysts on the day of ET
Exclusion criteria: not mentioned
Ovarian controlled hyperstimulation: donor oocytes, protocol not mentioned
Fertilisation: not mentioned
Stage of the embryo at transfer: blastocyst
Embryo processing: fresh
Number of embryos transferred: not mentioned (likely 2 from inclusion criteria)
Interventions Experimental: intrauterine injection of hCG 500 IU of 6 hours before the ET
Control: ET without any pre-intrauterine injection
Outcomes Clinical pregnancy
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-based randomisation
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Cambiaghi 2013 (Continued)
Allocation concealment (selection bias) Unclear risk Allocation concealment not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not mentioned
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Notmentioned, but unlikely to induce bias
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Very brief reporting of results
Selective reporting (reporting bias) Unclear risk No reporting on adverse events,miscarriage
and live birth
Other bias Unclear risk No reporting on baseline characteristics be-
tween groups
Hong 2014
Methods Design: 2-armed parallel RCT
Location: Reproductive Medicine Associates of New Jersey, USA
Period: August 2012 to December 2013
Power calculation: yes, but not met (778 embryos required, 473 embryos transferred)
Funding: not mentioned
Trial registration: NCT01643993
Publication type: full text
Participants Number: 300
Women’s age (mean years; experimental vs. control): 35.0 vs. 35.1
Inclusion criteria: all participants undergoing fresh or frozen ET within the ART pro-
gramme where the female partner was under 43 years of age
Exclusion criteria: women could not be simultaneously participating in another prospec-
tive clinical trial at the centre, but there were no other inclusion/exclusion criteria
Ovarian controlled hyperstimulation: not mentioned
Fertilisation: not mentioned
Stage of the embryo at transfer: blastocyst
Embryo processing: fresh and frozen/thawed
Number of embryos transferred: 1 or 2
Interventions Experimental: endometrial infusion of 20 µL ET media (synthetic serum substitute and
Medicult BlastAssist from Origio) laden with 500 IU of purified-urinary placental hCG
(Novarel, Ferring Pharmaceuticals) < 3 minutes before ET
Control: endometrial infusion of 20 µL ET media only
Outcomes Miscarriage and clinical pregnancy (converted from ongoing pregnancy)
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Hong 2014 (Continued)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A random number function was used to
create variable blocks of 4-8 with partici-
pants assigned to the 2 groups in a 1:1 al-
location
Allocation concealment (selection bias) Low risk Allocation concealment was achieved using
sequentially numbered, opaque, sealed en-
velopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Both the physician performing the transfer
and the participants were blinded to the
assigned treatment group throughout the
entirety
of the study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Notmentioned, but unlikely to induce bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss to follow-up
Selective reporting (reporting bias) Unclear risk No reports on live birth and adverse events
Other bias Unclear risk 25 participants declined to participate after
randomisation for various reasons
Janati 2013
Methods Design: 3-armed parallel RCT
Location: Research and Clinical Center for Infertility, Shahid Sadoughi University of
Medical Sciences, Yazd, Iran
Period: not mentioned
Power calculation: not mentioned
Funding: not mentioned
Trial registration: IRCT2012091310328N3
Publication type: abstract
Participants Number: 159
Women’s age: not mentioned
Inclusion criteria: women undergoing ART (from protocol)
Exclusion criteria: aged > 40 and < 20 years, FSH > 12 mIU/mL, infertility causes
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Janati 2013 (Continued)
except male or unexplained factor infertility, azoospermia, presence of uterine myoma,
endometriosis, hydrosalpinges, previous IVF/ICSI trials (successful or unsuccessful),
history of endocrine diseases (e.g. diabetes or thyroid dysfunction), women with previous
history of hysteroscopic operation due to submucosal myoma or intrauterine synechia
(from protocol)
Ovarian controlled hyperstimulation: antagonist protocol
Fertilisation: IVF or ICSI
Stage of the embryo at transfer: cleavage (from protocol)
Embryo processing: fresh (from protocol)
Number of embryos transferred: 2 or 3 (from protocol)
Interventions Experimental: hCG 500 IU (40 µL) intrauterine injection 7 minutes before ET
Experimental: hCG 1000 IU (40 µL) intrauterine injection 7 minutes before ET
Control: nothing before ET
Outcomes Clinical pregnancy, miscarriage
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants divided into 3 groups using ta-
ble of random numbers
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded (from protocol)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Notmentioned, but unlikely to induce bias
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Very brief reporting of results
Selective reporting (reporting bias) Unclear risk No reporting on live birth or adverse events
Other bias Unclear risk No reporting on baseline characteristics be-
tween groups
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Kokkali 2014
Methods Design: 2-armed parallel RCT
Location: Genesis Athens Hospital, Centre for Human Reproduction, Athens, Greece
Period: July 2012 to September 2013
Power calculation: no
Funding: Genesis Athens Clinic
Trial registration: not registered
Publication type: abstract
Participants Number: 194
Women’s age (years): > 40
Inclusion criteria: women aged > 40 years receiving donor eggs
Exclusion criteria: not mentioned
Ovarian controlled hyperstimulation: not mentioned
Fertilisation: not mentioned
Stage of the embryo at transfer: not mentioned
Embryo processing: not mentioned
Number of embryos transferred: not mentioned
Interventions Experimental: intrauterine hCG 500 IU injection 7 minutes before ET
Control: no intrauterine injection
Outcomes Clinical pregnancy
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was performed in a 1:1
fashion to 1 of 2 groups [...] prepared from
a computer-generated list
Allocation concealment (selection bias) Low risk Adequate allocation concealment
was assured from sequentially numbered,
opaque, sealed envelopes prepared from a
computer-generated list
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not blinded, but unlikely to induce bias
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Very brief reporting of results
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Kokkali 2014 (Continued)
Selective reporting (reporting bias) Unclear risk No reporting on live birth and adverse
events
Other bias Unclear risk No reporting on baseline characteristics be-
tween groups
Leao 2013
Methods Design: 2-armed parallel RCT
Location: IPGO, Sao Paulo, Brazil
Period: January to December 2012
Power calculation: no
Funding: not mentioned
Trial registration: not mentioned and not found
Publication type: abstract
Participants Number: 36
Women’s age: not mentioned
Inclusion criteria: women with 2 previous failures in IVF cycles with ET
Exclusion criteria: not mentioned
Ovarian controlled hyperstimulation: not mentioned
Fertilisation: not mentioned
Stage of the embryo at transfer: not mentioned
Embryo processing: not mentioned
Number of embryos transferred: not mentioned
Interventions Experimental: intrauterine injection of hCG 500 IU 6 hours before the ET
Control: women were forwarded straight to ET
Outcomes Clinical pregnancy
Notes Abstract presented as poster at 5th IVI International Congress, Seville, Spain, 2013
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisationmentionedwithout any de-
tails
Allocation concealment (selection bias) Unclear risk Allocation concealment not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not mentioned
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Leao 2013 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Notmentioned, but unlikely to induce bias
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Very brief reporting of results
Selective reporting (reporting bias) Unclear risk No reporting on adverse events,miscarriage
and live birth
Other bias High risk Participants number in each arm was not
reported, but deduced based on percent-
ages and previous study by the same team
Mansour 2011
Methods Design: 2 RCTs within the same study analysed as 4-armed parallel RCT
Location: The Egyptian IVF-ET Center, Cairo, Egypt
Period: January 2010 to January 2011
Power calculation: yes, but not met
Funding: The Egyptian IVF-ET Center
Trial registration: NCT01030393
Publication type: full text
Participants Number: 280 + 215 = 495
Women’s age (mean years; experimental 100, 200 vs. control; 500 vs. control): 29 vs.
28.5 vs. 29.1; 28.3 vs. 28.4
Inclusion criteria: women aged < 40 years old with infertility due to male factor
Exclusion criteria: previous IVF/ICSI trials, including a successful trial, azoospermia,
uterine myoma or previous myomectomy, endometriosis, or the presence of
hydrosalpinges
Ovarian controlled hyperstimulation: not mentioned
Fertilisation: ICSI
Stage of the embryo at transfer: cleavage
Embryo processing: fresh
Number of embryos transferred (mean; experimental 100, 200 vs. control; 500 vs. con-
trol): 2.9 vs. 2.8 vs. 2.9; 2.9 vs. 2.8
Interventions Experimental 100: 40 µL of tissue culture medium (G-2 plus ref. 10132, Vitrolife)
containing hCG 100 IU injected intrauterine approximately 7 minutes before ET
Experimental 200: 40 µL of tissue culture medium (G-2 plus ref. 10132, Vitrolife)
containing hCG 200 IU injected intrauterine approximately 7 minutes before ET
Experimental 500: 40 µL of tissue culture medium (G-2 plus ref. 10132, Vitrolife)
containing hCG 500 IU injected intrauterine approximately 7 minutes before ET
Control: no intrauterine hCG injection prior to ET
Outcomes Live birth, miscarriage, clinical pregnancy, ectopic pregnancy
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Mansour 2011 (Continued)
Notes Live birth rate established by personal communication with authors, June 2015. Study
publication reported number of deliveries, which included six women who had stillbirths
(3 in each group)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomised using sealed
dark envelopes into 2 groups
Allocation concealment (selection bias) Unclear risk Allocation concealment not mentioned.
Could explain different withdrawal rates
between groups
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not blinded, but unlikely to induce bias
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Women lost to follow-up live birth (similar
numbers between groups)
Selective reporting (reporting bias) Low risk Reported on all important outcomes
Other bias High risk Interim analysis with change of protocol
and premature ending of study. Relatively
high live birth rate in control group, reasons
unclear
Santibañez 2014
Methods Design: 2-armed parallel RCT
Location: Reproductive Medicine Centre PROCREA, Mexico City
Period: August 2011 to November 2012
Power calculation: yes
Funding: PROCREA
Trial registration: not mentioned and not found
Publication type: full text
Participants Number: 210
Women’s age (mean years; experimental vs. control): 36.4 vs. 37.3
Inclusion criteria: infertile women aged < 40 years who had an indication for an IVF/
ICSI
Exclusion criteria: azoospermia
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Santibañez 2014 (Continued)
Ovarian controlled hyperstimulation: indicated based on individual participant charac-
teristics
Fertilisation: IVF or ICSI
Stage of the embryo at transfer: cleavage
Embryo processing: fresh and frozen/thawed
Number of embryos transferred (mean): 2.1
Interventions Experimental: 20 µL of embryo culture medium (G-2, Vitrolife) that contained hCG
500 IU was administered intrauterine before ET
Control: no intrauterine hCG was administered
Outcomes Clinical pregnancy, ectopic pregnancy
Notes Authors mention “prospective observational study”, but the design was in fact RCT
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A simple randomisation sample and assign-
ment was generated in a computer-based
program
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not mentioned
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Notmentioned, but unlikely to induce bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk All women followed up till pregnancy test/
ultrasound scan
Selective reporting (reporting bias) Unclear risk No reporting on live birth and miscarriage
despite mentioning follow-up
Other bias Low risk Similar baseline characteristics between
groups after randomisation
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Singh 2014
Methods Design: 2-armed parallel RCT
Location: Bhopal Test Tube Baby Centre, Infertility, Bhopal, India
Period: 2006-2013
Power calculation: not mentioned
Funding: Bhopal Test Tube Baby Centre
Trial registration: BTTB/2006/19 (?)
Publication type: abstract
Participants Number: 216
Women’s age (mean years; experimental vs. control): 35 vs. 34.5 (from ESHRE 2014
oral presentation)
Inclusion criteria: infertile women aged < 42 years, with from recurrent implantation
failure
Exclusion criteria: not mentioned
Ovarian controlled hyperstimulation: based on individual participant characteristics
(from ESHRE 2014 oral presentation)
Fertilisation: ICSI
Stage of the embryo at transfer: cleavage
Embryo processing: not mentioned
Number of embryos transferred (mean; experimental vs. control): 2.7 vs. 2.5 (from
ESHRE 2014 oral presentation)
Interventions Experimental: intrauterine administration of rhCG 500 IU in 40 µL 5 minutes before
ET
Control: culture medium only administered before ET (from ESHRE 2014 oral presen-
tation)
Outcomes Clinical pregnancy, miscarriage, live birth (from ESHRE 2014 oral presentation)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomly divided into 2
groups using computer-generated list
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not mentioned
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Notmentioned, but unlikely to induce bias
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Singh 2014 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 0 women lost to follow-up
Selective reporting (reporting bias) Low risk Reported on all important outcomes
Other bias Low risk Similar baseline characteristics between
groups after randomisation
Wirleitner 2015a
Methods Design: 4-armed parallel RCT (same intervention on day 3 or 5)
Location: IVF Centers Prof. Zech, Bregenz, Austria
Period: February 2013 to February 2014
Power calculation: only met for day 5 administration
Funding: not mentioned
Trial registration: not mentioned and not found
Publication type: full text
Participants Number: 182 + 1004 = 1186
Women’s age (mean years; experimental vs. control): 36.1 vs. 35.5; 37.1 vs. 36.7
Inclusion criteria: fresh autologous blastocyst transfer on day 5 and woman age ≤ 43
years
Exclusion criteria: oocyte donation cycles and women with reported recurrent implan-
tation failure (≥ 3 negative IVF cycles)
Ovarian controlled hyperstimulation: GnRH agonist long protocol
Fertilisation: IVF or IMSI
Stage of the embryo at transfer: blastocyst
Embryo processing: fresh
Number of embryos transferred: 1 or 2
Interventions Experimental (day 3): intrauterine hCG 500 IU (Pregnyl, ORGANON, Netherlands)
dissolved in 40 µL embryo culture mediumG-2 PLUS (Vitrolife, Sweden) administered
on day 3 (2 days before ET)
Control (day 3): administration of 40 µL culture medium without hCG on day 3 (2
days before ET)
Experimental (day 5): intrauterine hCG 500 IU (Pregnyl, ORGANON, Netherlands)
dissolved in 40 µL embryo culture mediumG-2 PLUS (Vitrolife, Sweden) administered
on day 5 (3 minutes before ET)
Control (day 5): administration of 40 µL culture medium without hCG on day 3 (3
minutes before ET)
Outcomes Clinical pregnancy, miscarriage, live birth
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Wirleitner 2015a (Continued)
Random sequence generation (selection
bias)
Low risk Randomisation was done electronically
with a random number generator
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants blinded, but not the personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not blinded, but unlikely to induce bias
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 19 participants lost to follow-up
Selective reporting (reporting bias) Low risk Reports on all relevant outcomes
Other bias Low risk Baseline characteristics of the participants
were comparable between 2 study groups
Wirleitner 2015b
Methods Design: 2-armed parallel RCT
Location: IVF-Centers Prof. Zech, Bregenz, Austria
Period: not mentioned
Power calculation: yes
Funding: funded by hospital/clinic(s) - this study was not externally funded
Trial registration: CRT:355
Publication type: abstract
Participants Number: 480
Women’s age (mean years; experimental vs. control): 40.3 vs. 40.4
Inclusion criteria: women aged 38-43 years
Exclusion criteria: recurrent implantation failure
Ovarian controlled hyperstimulation: GnRH agonist long protocol
Fertilisation: IMSI
Stage of the embryo at transfer: blastocyst
Embryo processing: fresh
Number of embryos transferred: 1 or 2
Interventions Experimental: intrauterine hCG 500 IU dissolved in 40 µL embryo culture medium
administered 3 minutes before ET
Control: administration of 40 µL culture medium without hCG 3 minutes before ET
Outcomes Clinical pregnancy, miscarriage, live birth
Notes
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Wirleitner 2015b (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation was mentioned without
further details
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not blinded, but unlikely to induce bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants were followed up
Selective reporting (reporting bias) Low risk Reports on all relevant outcomes
Other bias Low risk Baseline characteristics of the participants
were comparable between 2 study groups
Zarei 2014
Methods Design: 2-armed parallel RCT
Location: Reproductive Medicine Center of Mother and Child Hospital, Shiraz, Iran
Period: December 2011 to November 2012
Power calculation: yes
Funding: Shiraz University of Medical Sciences
Trial registration: IRCT2012121711790N1
Publication type: full text
Participants Number: 210
Women’s age (mean years; experimental vs. control): 29.9 vs. 31.2
Inclusion criteria: 18-40-year-old women with infertility
Exclusion criteria: women with from autoimmune disorders, endocrinopathies, who had
previous successful IVF/ICSI trials, endometriosis, azoospermia and hydrosalpinges
Ovarian controlled hyperstimulation: not mentioned
Fertilisation: ICSI
Stage of the embryo at transfer: cleavage
Embryo processing: not mentioned (likely fresh)
Number of embryos transferred (mean; experimental vs. control): 6.1 vs. 5.7
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Zarei 2014 (Continued)
Interventions Experimental: rhCG 250 µg (0.5 mL, 6500 IU) (Ovitrelle, Merck Serono, France)
through intrauterine injection 12 minutes before ET
Control: intrauterine injection of normal saline (0.5 mL) 12 minutes before ET
Outcomes Clinical pregnancy, miscarriage, ectopic pregnancy, still birth
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The participantswere randomly assigned to
2 study groups using a computerised ran-
dom digit generator based on their regis-
tration number in order of referral
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The syringes with volume of 0.5 mL from
each groupwere prepared by fellowship stu-
dent and injected blinded by the attending
gynaecologist
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blinding mentioned (? women ?
outcome assessors - in addition to gynae-
cologists performing the transfer), unlikely
to induce bias
Incomplete outcome data (attrition bias)
All outcomes
High risk 23/105 participants in intrauterine rhCG
group and 7/105 participants in placebo
group were lost to follow-up after receiving
the allocated treatment (unclear why)
Selective reporting (reporting bias) Unclear risk No report on live birth
Other bias Low risk Baseline characteristics of the participants
were comparable between 2 study groups
ART: assisted reproductive technology; ET: embryo transfer; ESHRE: European Society of Human Reproduction and Embryology;
FSH: follicle-stimulating hormone; GnRH: gonadotropin-releasing hormone; hCG: human chorionic gonadotropin; ICSI: intra-
cytoplasmic sperm injection; IMSI: intracytoplasmic morphologically selected sperm injection; IU: international unit; IVF: in vitro
fertilisation; RCT: randomised controlled trial; rhCG: recombinant human chorionic gonadotropin.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Jeong 2013 Retrospective
Li 2013 Not randomised
Rebolloso 2013 Not randomised
Riboldi 2013 Not randomised
Ye 2015 Meta-analysis
Characteristics of studies awaiting assessment [ordered by study ID]
Badehnoosh 2014
Methods Design: 2-armed parallel RCT
Location: Avicenna Infertility Clinic, Tehran, Iran
Period: not mentioned
Power calculation: not mentioned
Funding: not mentioned
Trial registration: not mentioned and not found
Publication type: abstract
Participants Number: 80
Women’s age (mean years; experimental vs. control): 29.5 vs. 29.3
Inclusion criteria: women undergoing ICSI
Exclusion criteria: not mentioned
Ovarian controlled hyperstimulation: not mentioned
Fertilisation: ICSI
Stage of the embryo at transfer: not mentioned
Embryo processing: not mentioned
Number of embryos transferred (mean; experimental vs. control): 2.9 vs. 2.8
Interventions Experimental: intrauterine injection of hCG 500 IU dissolved in 40 µL of ET media 10 minutes before ET
Control: 40 µL of ET media 10 minutes before ET
Outcomes Implantation rate defined as positive pregnancy test at 2 weeks after ET (biochemical pregnancy)
Notes We emailed the authors in February 2016 for more information on study design and outcomes
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Bhat 2014
Methods Design: 2-armed parallel RCT
Location: Radhakrishna Multispecialty hospital and IVF Centre in Bengaluru in Southern India
Period: April 2013 to March 2014
Power calculation: not mentioned
Funding: none
Trial registration: Not mentioned and not found.
Publication type: full text
Participants Number: 32
Women’s age (mean years; experimental vs. control): 29.6 vs. 29.6
Inclusion criteria: women undergoing IVF
Exclusion criteria: not mentioned
Ovarian controlled hyperstimulation: not mentioned
Fertilisation: IVF or ICSI
Stage of the embryo at transfer: cleavage
Embryo processing: fresh and frozen/thawed
Number of embryos transferred (mean; experimental vs. control): 2.9 vs. 2.9
Interventions Experimental: intrauterine administration of hCG 500 IU 7 minutes before ET
Control: ET without hCG
Outcomes Fertilisation rate
Notes We emailed the authors in February 2016 for more information on study design and outcomes. No reply has yet
been received
ET: embryo transfer; hCG: human chorionic gonadotropin; ICSI: intracytoplasmic sperm injection; IU: international unit; IVF: in
vitro fertilisation; RCT: randomised controlled trial.
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D A T A A N D A N A L Y S E S
Comparison 1. Intrauterine human chorionic gonadotropin (hCG) versus no hCG
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Live birth 5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Cleavage stage: hCG <
500 IU
1 280 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.58, 1.01]
1.2 Cleavage stage: hCG ≥
500 IU
3 914 Risk Ratio (M-H, Random, 95% CI) 1.57 [1.32, 1.87]
1.3 Blastocyst stage: hCG ≥
500 IU
2 1666 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.80, 1.04]
2 Miscarriage 7 3395 Risk Ratio (M-H, Random, 95% CI) 1.09 [0.83, 1.43]
3 Miscarriage per clinical
pregnancy
7 1450 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.77, 1.30]
4 Clinical pregnancy 10 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Cleavage stage: hCG <
500 IU
1 280 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.70, 1.10]
4.2 Cleavage stage: hCG ≥
500 IU
7 1414 Risk Ratio (M-H, Random, 95% CI) 1.41 [1.25, 1.58]
4.3 Blastocyst stage: hCG ≥
500 IU
3 1991 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.86, 1.06]
5 Complications: intrauterine
death
2 978 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.80 [0.33, 1.92]
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Analysis 1.1. Comparison 1 Intrauterine human chorionic gonadotropin (hCG) versus no hCG, Outcome 1
Live birth.
Review: Intrauterine administration of human chorionic gonadotropin (hCG) for subfertile women undergoing assisted reproduction
Comparison: 1 Intrauterine human chorionic gonadotropin (hCG) versus no hCG
Outcome: 1 Live birth
Study or subgroup Intrauterine hCG No hCG Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Cleavage stage: hCG < 500 IU
Mansour 2011 (1) 35/92 23/47 49.2 % 0.78 [ 0.53, 1.15 ]
Mansour 2011 (2) 35/93 24/48 50.8 % 0.75 [ 0.51, 1.11 ]
Subtotal (95% CI) 185 95 100.0 % 0.76 [ 0.58, 1.01 ]
Total events: 70 (Intrauterine hCG), 47 (No hCG)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 1.91 (P = 0.056)
2 Cleavage stage: hCG ≥ 500 IU
Aaleyasin 2015 98/240 60/243 43.6 % 1.65 [ 1.27, 2.16 ]
Mansour 2011 (3) 66/108 45/107 43.1 % 1.45 [ 1.11, 1.90 ]
Singh 2014 34/108 20/108 13.3 % 1.70 [ 1.05, 2.76 ]
Subtotal (95% CI) 456 458 100.0 % 1.57 [ 1.32, 1.87 ]
Total events: 198 (Intrauterine hCG), 125 (No hCG)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.59, df = 2 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 5.01 (P < 0.00001)
3 Blastocyst stage: hCG ≥ 500 IU
Wirleitner 2015a (4) 31/89 34/93 11.0 % 0.95 [ 0.64, 1.41 ]
Wirleitner 2015a (5) 188/510 198/494 68.3 % 0.92 [ 0.79, 1.08 ]
Wirleitner 2015b 68/255 68/225 20.7 % 0.88 [ 0.66, 1.17 ]
Subtotal (95% CI) 854 812 100.0 % 0.92 [ 0.80, 1.04 ]
Total events: 287 (Intrauterine hCG), 300 (No hCG)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.11, df = 2 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 1.34 (P = 0.18)
Test for subgroup differences: Chi2 = 29.39, df = 2 (P = 0.00), I2 =93%
0.5 0.7 1 1.5 2
Favours no hCG Favours intrauterine hCG
(1) hCG 100 IU
(2) hCG 200 IU
(3) hCG 500 IU
(4) Day 3 hCG administration
(5) Day 5 hCG administration
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Analysis 1.2. Comparison 1 Intrauterine human chorionic gonadotropin (hCG) versus no hCG, Outcome 2
Miscarriage.
Review: Intrauterine administration of human chorionic gonadotropin (hCG) for subfertile women undergoing assisted reproduction
Comparison: 1 Intrauterine human chorionic gonadotropin (hCG) versus no hCG
Outcome: 2 Miscarriage
Study or subgroup Intrauterine hCG No hCG Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Aaleyasin 2015 15/240 12/243 13.8 % 1.27 [ 0.61, 2.65 ]
Hong 2014 17/161 11/164 14.2 % 1.57 [ 0.76, 3.26 ]
Mansour 2011 (1) 8/92 2/47 3.3 % 2.04 [ 0.45, 9.24 ]
Mansour 2011 (2) 9/108 10/107 10.1 % 0.89 [ 0.38, 2.11 ]
Mansour 2011 (3) 8/93 2/48 3.3 % 2.06 [ 0.46, 9.34 ]
Singh 2014 6/108 5/108 5.6 % 1.20 [ 0.38, 3.81 ]
Wirleitner 2015a (4) 25/510 30/494 28.1 % 0.81 [ 0.48, 1.35 ]
Wirleitner 2015a (5) 2/89 3/93 2.4 % 0.70 [ 0.12, 4.07 ]
Wirleitner 2015b 18/255 15/225 17.1 % 1.06 [ 0.55, 2.05 ]
Zarei 2014 2/105 2/105 2.0 % 1.00 [ 0.14, 6.97 ]
Total (95% CI) 1761 1634 100.0 % 1.09 [ 0.83, 1.43 ]
Total events: 110 (Intrauterine hCG), 92 (No hCG)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.30, df = 9 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.60 (P = 0.55)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours intrauterine hCG Favours no hCG
(1) hCG 100 IU
(2) hCG 500 IU
(3) hCG 200 IU
(4) Day 5 hCG administration
(5) Day 3 hCG administration
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Analysis 1.3. Comparison 1 Intrauterine human chorionic gonadotropin (hCG) versus no hCG, Outcome 3
Miscarriage per clinical pregnancy.
Review: Intrauterine administration of human chorionic gonadotropin (hCG) for subfertile women undergoing assisted reproduction
Comparison: 1 Intrauterine human chorionic gonadotropin (hCG) versus no hCG
Outcome: 3 Miscarriage per clinical pregnancy
Study or subgroup Intrauterine hCG No hCG Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Aaleyasin 2015 15/120 12/78 13.8 % 0.81 [ 0.40, 1.64 ]
Hong 2014 17/87 11/79 14.2 % 1.40 [ 0.70, 2.81 ]
Mansour 2011 (1) 8/49 2/28 3.1 % 2.29 [ 0.52, 10.02 ]
Mansour 2011 (2) 9/80 10/63 9.7 % 0.71 [ 0.31, 1.64 ]
Mansour 2011 (3) 8/45 2/27 3.1 % 2.40 [ 0.55, 10.48 ]
Singh 2014 6/40 5/25 5.9 % 0.75 [ 0.26, 2.20 ]
Wirleitner 2015a (4) 2/33 3/37 2.3 % 0.75 [ 0.13, 4.20 ]
Wirleitner 2015a (5) 25/213 30/228 27.7 % 0.89 [ 0.54, 1.47 ]
Wirleitner 2015b 18/86 15/83 18.1 % 1.16 [ 0.63, 2.14 ]
Zarei 2014 2/29 2/20 1.9 % 0.69 [ 0.11, 4.50 ]
Total (95% CI) 782 668 100.0 % 1.00 [ 0.77, 1.30 ]
Total events: 110 (Intrauterine hCG), 92 (No hCG)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.42, df = 9 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.98)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours intrauterine hCG Favours no hCG
(1) hCG 200 IU
(2) hCG 500 IU
(3) hCG 100 IU
(4) Day 3 hCG administration
(5) Day 5 hCG administration
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Analysis 1.4. Comparison 1 Intrauterine human chorionic gonadotropin (hCG) versus no hCG, Outcome 4
Clinical pregnancy.
Review: Intrauterine administration of human chorionic gonadotropin (hCG) for subfertile women undergoing assisted reproduction
Comparison: 1 Intrauterine human chorionic gonadotropin (hCG) versus no hCG
Outcome: 4 Clinical pregnancy
Study or subgroup Intrauterine hCG No hCG Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Cleavage stage: hCG < 500 IU
Mansour 2011 (1) 49/93 28/48 52.5 % 0.90 [ 0.66, 1.23 ]
Mansour 2011 (2) 45/92 27/47 47.5 % 0.85 [ 0.62, 1.18 ]
Subtotal (95% CI) 185 95 100.0 % 0.88 [ 0.70, 1.10 ]
Total events: 94 (Intrauterine hCG), 55 (No hCG)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.07, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 1.14 (P = 0.25)
2 Cleavage stage: hCG ≥ 500 IU
Aaleyasin 2015 120/240 78/243 27.3 % 1.56 [ 1.25, 1.95 ]
Cambiaghi 2013 18/22 14/22 9.8 % 1.29 [ 0.89, 1.87 ]
Leao 2013 (3) 7/18 5/18 1.5 % 1.40 [ 0.54, 3.60 ]
Mansour 2011 (4) 80/108 63/107 36.0 % 1.26 [ 1.04, 1.53 ]
Santiba ez 2014 51/101 36/109 12.4 % 1.53 [ 1.10, 2.13 ]
Singh 2014 40/108 25/108 7.6 % 1.60 [ 1.05, 2.44 ]
Zarei 2014 29/105 20/105 5.4 % 1.45 [ 0.88, 2.39 ]
Subtotal (95% CI) 702 712 100.0 % 1.41 [ 1.25, 1.58 ]
Total events: 345 (Intrauterine hCG), 241 (No hCG)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.18, df = 6 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 5.76 (P < 0.00001)
3 Blastocyst stage: hCG ≥ 500 IU
Hong 2014 (5) 87/161 79/164 22.6 % 1.12 [ 0.91, 1.39 ]
Wirleitner 2015a (6) 213/510 228/494 52.4 % 0.90 [ 0.79, 1.04 ]
Wirleitner 2015a (7) 33/89 37/93 7.6 % 0.93 [ 0.64, 1.35 ]
Wirleitner 2015b 86/255 83/225 17.5 % 0.91 [ 0.72, 1.17 ]
Subtotal (95% CI) 1015 976 100.0 % 0.95 [ 0.86, 1.06 ]
Total events: 419 (Intrauterine hCG), 427 (No hCG)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.91, df = 3 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.92 (P = 0.36)
Test for subgroup differences: Chi2 = 28.83, df = 2 (P = 0.00), I2 =93%
0.5 0.7 1 1.5 2
Favours no hCG Favours intrauterine hCG
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(1) hCG 200 IU
(2) hCG 100 IU
(3) Participants number in each arm estimated from percentages and previous study by the same team.
(4) hCG 500 IU
(5) Clinical pregnancy converted from ongoing pregnancy.
(6) Day 5 hCG administration
(7) Day 3 hCG administration
Analysis 1.5. Comparison 1 Intrauterine human chorionic gonadotropin (hCG) versus no hCG, Outcome 5
Complications: intrauterine death.
Review: Intrauterine administration of human chorionic gonadotropin (hCG) for subfertile women undergoing assisted reproduction
Comparison: 1 Intrauterine human chorionic gonadotropin (hCG) versus no hCG
Outcome: 5 Complications: intrauterine death
Study or subgroup Intrauterine hCG No hCG
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Aaleyasin 2015 7/240 6/243 62.9 % 1.19 [ 0.39, 3.57 ]
Mansour 2011 (1) 1/92 2/47 13.1 % 0.23 [ 0.02, 2.51 ]
Mansour 2011 (2) 1/93 0/48 4.5 % 4.55 [ 0.07, 284.96 ]
Mansour 2011 (3) 1/108 3/107 19.6 % 0.36 [ 0.05, 2.59 ]
Total (95% CI) 533 445 100.0 % 0.80 [ 0.33, 1.92 ]
Total events: 10 (Intrauterine hCG), 11 (No hCG)
Heterogeneity: Chi2 = 2.86, df = 3 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.50 (P = 0.62)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours intrauterine hCG Favours no hCG
(1) hCG 100 IU
(2) hCG 200 IU
(3) hCG 500 IU
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A P P E N D I C E S
Appendix 1. Cochrane Gynaecology and Fertility Group (CGF) Specialised Register search strategy
PROCITE Platform
From inception to 10 November 2015
Keywords CONTAINS “IVF” or “in vitro fertilization” or “in-vitro fertilisation” or “ICSI” or “intracytoplasmic sperm injection”
or “ET” or “Embryo” or “in-vitro fertilization” or “Embryo Transfer” or “Embryo Transfer-uterine” or “blastocyst transfer” or Title
CONTAINS “IVF” or “in vitro fertilization” or “in-vitro fertilisation” or “ICSI” or “intracytoplasmic sperm injection” or “Embryo” or
“in-vitro fertilization” or “ET” or “Embryo” or “in-vitro fertilization” or “Embryo Transfer” or “Embryo Transfer-uterine” or “blastocyst
transfer”
AND
Keywords CONTAINS “HCG ” or “human chorionic gonadotrophin” or “human chorionic gonadotropin” or “recombinant HCG”
or “rhCG” or Title CONTAINS “HCG ” or “human chorionic gonadotrophin” or “human chorionic gonadotropin” or “recombinant
HCG” or “rhCG”
AND
Keywords CONTAINS “intrauterine human chorionic gonadotrophin” or “intrauterine” or “Intrauterine injection” or “intrauterine
instillation ”or “uterine cavity injection” or “endometrial” or “Endometrium” or “uterine” or Title CONTAINS “intrauterine human
chorionic gonadotrophin” or “intrauterine” or “Intrauterine injection” or “intrauterine instillation ”or “uterine cavity injection” or
“Endometrium” or “uterine” (17 hits)
Appendix 2. CENTRAL search strategy
OVID Platform
From inception to 10 November 2015
1 exp embryo transfer/ or exp fertilization in vitro/ or exp sperm injections, intracytoplasmic/ (1756)
2 embryo transfer$.tw. (1200)
3 in vitro fertili?ation.tw. (1610)
4 ivf-et.tw. (324)
5 (ivf or et).tw. (13581)
6 icsi.tw. (992)
7 intracytoplasmic sperm injection$.tw. (538)
8 (blastocyst adj2 transfer$).tw. (130)
9 or/1-8 (15067)
10 exp Chorionic Gonadotropin/ad, tu, th [Administration & Dosage, Therapeutic Use, Therapy] (22)
11 (Human Chorionic Gonadotrop?in adj7 intrauter$).tw. (33)
12 (Human Chorionic Gonadotrop?in adj7 uter$).tw. (8)
13 (Human Chorionic Gonadotrop?in adj7 intra-uter$).tw. (2)
14 ((endometri$ adj2 infusion$) and chorionic).tw. (3)
15 ((endometri$ adj2 ?instillation) and chorionic).tw. (0)
16 ((intra?uter$ adj2 infusion$) and chorionic).tw. (0)
17 ((intra?uter$ adj2 ?instillation) and chorionic).tw. (2)
18 ((endometri$ adj2 injection$) and chorionic).tw. (0)
19 ((intra?uter$ adj2 injection$) and chorionic).tw. (9)
20 ((intra?uter$ adj2 administration) and chorionic).tw. (5)
21 ((endometri$ adj2 administration) and chorionic).tw. (3)
22 (intrauter$ adj7 ?hcg).tw. (39)
23 (intra-uter$ adj7 ?hcg).tw. (4)
24 (uter$ adj7 ?hcg).tw. (25)
25 or/10-24 (115)
26 9 and 25 (45)
46Intrauterine administration of human chorionic gonadotropin (hCG) for subfertile women undergoing assisted reproduction (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Appendix 3. MEDLINE search strategy
OVID Platform
From inception to 10 November 2015
1 exp embryo transfer/ or exp fertilization in vitro/ or exp sperm injections, intracytoplasmic/ (34811)
2 embryo transfer$.tw. (9012)
3 in vitro fertili?ation.tw. (18370)
4 ivf-et.tw. (1958)
5 (ivf or et).tw. (200229)
6 icsi.tw. (6135)
7 intracytoplasmic sperm injection$.tw. (5460)
8 (blastocyst adj2 transfer$).tw. (638)
9 or/1-8 (226616)
10 exp Chorionic Gonadotropin/ad, tu, th [Administration & Dosage, Therapeutic Use, Therapy] (4588)
11 (Human Chorionic Gonadotrop?in adj7 intrauter$).tw. (64)
12 (Human Chorionic Gonadotrop?in adj7 uter$).tw. (136)
13 (Human Chorionic Gonadotrop?in adj7 intra-uter$).tw. (0)
14 ((endometri$ adj2 infusion$) and chorionic).tw. (1)
15 ((endometri$ adj2 ?instillation) and chorionic).tw. (0)
16 ((intra?uter$ adj2 infusion$) and chorionic).tw. (2)
17 ((intra?uter$ adj2 ?instillation) and chorionic).tw. (5)
18 ((endometri$ adj2 injection$) and chorionic).tw. (4)
19 ((intra?uter$ adj2 injection$) and chorionic).tw. (10)
20 ((intra?uter$ adj2 administration) and chorionic).tw. (9)
21 ((endometri$ adj2 administration) and chorionic).tw. (7)
22 (intrauter$ adj7 ?hcg).tw. (154)
23 (intra-uter$ adj7 ?hcg).tw. (13)
24 (uter$ adj7 ?hcg).tw. (304)
25 or/10-24 (5100)
26 9 and 25 (1371)
27 randomised controlled trial.pt. (415727)
28 controlled clinical trial.pt. (92036)
29 randomized.ab. (337724)
30 randomised.ab. (68893)
31 placebo.tw. (174138)
32 clinical trials as topic.sh. (179636)
33 randomly.ab. (243672)
34 trial.ti. (148881)
35 (crossover or cross-over or cross over).tw. (66446)
36 or/27-35 (1054341)
37 exp animals/ not humans.sh. (4140674)
38 36 not 37 (972043)
39 26 and 38 (284)
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Appendix 4. EMBASE search strategy
OVID Platform
From inception to 10 November 2015
1 exp embryo transfer/ or exp fertilization in vitro/ or exp intracytoplasmic sperm injection/ (58694)
2 embryo$ transfer$.tw. (14774)
3 in vitro fertili?ation.tw. (22851)
4 ivf-et.tw. (2625)
5 icsi.tw. (11364)
6 intracytoplasmic sperm injection$.tw. (7117)
7 (blastocyst adj2 transfer$).tw. (1412)
8 (ivf or et).tw. (563610)
9 or/1-8 (601227)
10 (Human Chorionic Gonadotrop?in adj7 intrauter$).tw. (96)
11 (Human Chorionic Gonadotrop?in adj7 uter$).tw. (133)
12 (intrauter$ adj7 ?hcg).tw. (230)
13 chorionic gonadotropin/dt, ut [Drug Therapy, Intrauterine Drug Administration] (4564)
14 (uter$ adj3 ?hcg).tw. (116)
15 ((endometri$ adj2 infusion$) and chorionic).tw. (2)
16 ((endometri$ adj2 ?instillation) and chorionic).tw. (0)
17 ((intra?uter$ adj2 infusion$) and chorionic).tw. (3)
18 ((intra?uter$ adj2 ?instillation) and chorionic).tw. (5)
19 ((endometri$ adj2 injection$) and chorionic).tw. (5)
20 ((intra?uter$ adj2 injection$) and chorionic).tw. (29)
21 ((intra?uter$ adj2 administration) and chorionic).tw. (22)
22 ((endometri$ adj2 administration) and chorionic).tw. (12)
23 or/10-22 (5050)
24 9 and 23 (2018)
25 Clinical Trial/ (852930)
26 Randomized Controlled Trial/ (388340)
27 exp randomization/ (68781)
28 Single Blind Procedure/ (21262)
29 Double Blind Procedure/ (124741)
30 Crossover Procedure/ (45104)
31 Placebo/ (266177)
32 Randomi?ed controlled trial$.tw. (126646)
33 Rct.tw. (18757)
34 random allocation.tw. (1466)
35 randomly allocated.tw. (23611)
36 allocated randomly.tw. (2073)
37 (allocated adj2 random).tw. (741)
38 Single blind$.tw. (16599)
39 Double blind$.tw. (156489)
40 ((treble or triple) adj blind$).tw. (502)
41 placebo$.tw. (223655)
42 prospective study/ (313729)
43 or/25-42 (1520537)
44 case study/ (34667)
45 case report.tw. (294447)
46 abstract report/ or letter/ (944413)
47 or/44-46 (1266917)
48 43 not 47 (1480399)
49 24 and 48 (631)
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Appendix 5. CINAHL search strategy
EBSCO Platform
From inception to 10 November 2015
# Query Results
S15 S8 AND S14 41
S14 S9 OR S10 OR S11 OR S12 OR S13 1,464
S13 TX(Chorionic Gonadotrop?in N7 intrauter*) 0
S12 TX(Chorionic Gonadotrop?in N7 uter*) 2
S11 TX(Human Chorionic Gonadotrop?in N7 intrauter*) 967
S10 TX(Human Chorionic Gonadotrop?in N7 intrauter*) 0
S9 (MM “Gonadotropins, Chorionic”) 496
S8 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 3,690
S7 TX embryo* N3 transfer* 754
S6 TX ovar* N3 hyperstimulat* 334
S5 TX ovari* N3 stimulat* 243
S4 TX IVF or TX ICSI 1,234
S3 (MM “Fertilization in Vitro”) 1,435
S2 TX vitro fertilization 2,821
S1 TX vitro fertilisation 265
Appendix 6. PsycINFO search strategy
OVID Platform
From inception to 10 November 2015
1 exp reproductive technology/ (1380)
2 in vitro fertili?ation.tw. (567)
3 icsi.tw. (50)
4 intracytoplasmic sperm injection$.tw. (42)
5 (blastocyst adj2 transfer$).tw. (4)
6 (embryo$ adj2 transfer$).tw. (122)
7 or/1-6 (1591)
8 exp Gonadotropic Hormones/ (3783)
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9 (Human Chorionic Gonadotrop?in adj7 intrauter$).tw. (0)
10 (Human Chorionic Gonadotrop?in adj7 uter$).tw. (0)
11 (intrauter$ adj7 ?hcg).tw. (0)
12 (uter$ adj7 ?hcg).tw. (0)
13 or/8-12 (3783)
14 7 and 13 (7)
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Slight narrowing of the Cochrane Gynaecology and Fertility Group Specialised Register search strategy.
We performed a subgroup analysis based on IC-hCG dose to address the heterogeneity.
For outcomes with event rates below 1%, we used the Peto one-step odds ratio (OR) method to calculate the combined outcome with
95% confidence interval.
If a study included multiple treatment arms receiving different doses of hCG, we split the control group proportionally with the
experimental groups in order to avoid analysing control participants in duplicate.
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